Patients and Methods: Twelve patients with neuroblastoma were treated after relapse (five patients) or after induction therapy (seven patients). Eight patients had metastatic and four had localized disease at the time of therapy. All patients received 131 I-MIBG 12 mCi/kg on day ؊21, followed by carboplatin (1,500 mg/m 2 ), etoposide (800 mg/m 2 ), and melphalan (210 mg/m 2 ) administered from day ؊7 to day ؊4. Autologous peripheral-blood stem cells or bone marrow were infused on day 0. Engraftment, toxicity, and response rates were evaluated.
N
EUROBLASTOMA IS the most common extracranial solid tumor of childhood, accounting for 8% to 10% of all childhood malignancies. 1 Despite intensive chemotherapy with autologous bone marrow transplantation followed by 13-cis-retinoic acid, the 3-year progression-free survival in patients over 1 year of age who present with metastatic disease remains less than 35%. 2, 3 Patients who did not achieve a complete response (CR) to induction therapy and patients who relapse after a prior transplantation have a less than 20% event-free survival rate. [4] [5] [6] Newer approaches for treating such high-risk patients are needed.
Studies at the University of Michigan in the 1970s identified a number of guanethidine derivatives, including metaiodobenzylguanidine (MIBG) , that exhibited binding with adrenal medullary tissue. 7 Structurally similar to norepinephrine, MIBG was found to concentrate within the neurosecretory granules of catecholamine-producing cells. 7, 8 Subsequent scintigraphic studies in the 1970s and 1980s demonstrated the effectiveness of MIBG for the localization of pheochromocytomas, neuroblastomas, and other neuroendocrine tumors. [9] [10] [11] [12] [13] [14] [15] [16] Approximately 90% of neuroblastomas concentrate MIBG, with uptake well described in both primary tumor sites and metastases. 17 MIBG concentrates in tumors with favorable or unfavorable histologic patterns, amplified or nonamplified MYCN oncogene expression, and low-stage as well as advanced-stage disease.
17,18
The use of iodine-131-metaiodobenzylguanidine ( 131 I-MIBG) as a therapeutic agent for patients with advanced neuroblastoma has been reported in Europe, the University of California San Francisco, and the University of Michigan. [19] [20] [21] [22] [23] [24] [25] [26] [27] The majority of these trials were single-agent studies, with response rates ranging from 10% to 50%. The durations of response were often brief, ranging from 100 to over 500 days. Reported toxicity was mild, including nausea and vomiting, myelosuppression, and occasional hypothyroidism. To date, dose escalation of 131 I-MIBG therapy for neuroblastoma has failed to achieve nonhematologic doselimiting toxicity. 23 Given the poor progression-free survival for patients with refractory or relapsed disease, attempts to improve prognosis with a combination of 131 I-MIBG, myeloablative chemotherapy, and autologous bone marrow transplantation have been reported. 24, 25, 27 The current pilot trial combined a fixed dose of 131 I-MIBG with a high-dose chemotherapy regimen of carboplatin, etoposide, and melphalan followed by autologous marrow or stem-cell rescue. Toxicity, engraftment parameters, and response rates were determined for this patient group.
PATIENTS AND METHODS

Patient Population
Eligible patients were 1 to 18 years of age, had histologically proven neuroblastoma that had relapsed or progressed with induction therapy, and had not achieved complete remission with induction therapy. Patients were required to have evidence of MIBG avidity, as determined by a 123 I-MIBG or 131 I-MIBG imaging scan, before study entry. Patients who had undergone a previous autologous transplantation were eligible, provided that more than 6 months had elapsed from their initial transplantation. A glomerular filtration rate or 24-hour creatinine clearance Ն 60 mL/min/1.73 m 2 was required at study entry. The study was approved by the institutional review board at the University of Michigan, and informed consent was obtained from all parents/guardians.
Autologous Marrow or Stem-Cell Harvest
A minimum of 4.0 ϫ 10 6 CD34 ϩ cells/kg (or 2.0 ϫ 10 8 mononuclear cells/kg) were harvested and cryopreserved before study entry, with 2.0 ϫ 10 6 CD34 ϩ cells/kg held in reserve in the event of delayed engraftment after transplantation. Harvested bone marrow cells were treated ex vivo with sedimentation, filtration, and immunomagnetic beads at Children's Hospital of Los Angeles.
28 Peripheral stem-cell harvests were not required to undergo ex vivo purging. All marrow and stem-cell products were determined to be tumor-free by immunocytologic methods.
29
I-MIBG Preparation
The MIBG was synthesized and exchange labeled in the Phoenix Laboratory at the University of Michigan Medical Center. The 131 I was supplied by MDS Nordion (Kanata, Ontario, Canada). The specific activity of 131 I-MIBG was 9.0 Ci/mmol with a free iodide content of less than 5%. All products underwent radionuclidic, radiochemical, sterility, and pyrogenicity testing in the University of Michigan Nuclear Pharmacy. In all cases, the prescribed dose of 131 I-MIBG was 12 mCi/kg, on the basis of the patient's actual body weight. However, after conjugation of radiolabeled iodine to MIBG, the actual administered dosage varied within 5% of the prescribed dose. I-MIBG dose (12 mCi/kg) was diluted in 50 mL of normal saline, and infused intravenously via a central catheter over 120 minutes. Patients remained behind radiation shielding until radiation emissions were measured to be less than 3 mR/h at a 1-m distance from the patient. At that point, patients were discharged from isolation.
Treatment With 131 I-MIBG
Myeloablative Chemotherapy Administration
Patients were subsequently admitted to the bone marrow transplant unit on day Ϫ7 before transplantation to receive myeloablative chemotherapy. Carboplatin (total dose, 1,500 mg/m 2 ) and etoposide (total dose, 800 mg/m 2 ) were administered as 96-hour continuous infusions on day Ϫ7 through day Ϫ4. Patients with a creatinine clearance Ն 100 mL/min/1.73 m 2 received carboplatin at 375 mg/m 2 /d. Patients with a creatinine clearance 60 to 99 mL/min/1.73 m 2 received carboplatin dosed on the Calvert formula, targeting an area under the curve of 3.3 mg/mL/min per day.
30 Melphalan (70 mg/m 2 /d) was administered by intravenous bolus infusion on days Ϫ7, Ϫ6, and Ϫ5. Autologous marrow or peripheral stem cells were infused on day 0.
Supportive Care
All patients received granulocyte colony-stimulating factor 5 g/kg subcutaneously daily, beginning day 6 after transplantation and continuing until the absolute neutrophil count (ANC) was greater than 1.0 ϫ 10 3 /L for 2 consecutive days. Prophylactic fluconazole and acyclovir were administered through day 28. Pneumocystis carinii pneumonia prophylaxis with trimethoprim-sulfamethoxazole (or pentamidine) was administered to all patients for 6 months after transplantation.
Posttransplant Therapy
Patients were treated with oral cis-retinoic acid (120 to 160 mg/m 2 / d), administered over 14-day intervals, beginning approximately day 100 after transplantation. Cis-retinoic acid was continued for 1 year in patients who remained in complete remission.
Toxicity, Engraftment, and Response Evaluation
All patients underwent a 123 I-or 131 I-MIBG scan, computed tomography or magnetic resonance imaging scan of sites of bulk disease, and bilateral bone marrow aspirate and biopsies with immunocytology at the time of study entry. For response assessment, these studies were repeated at 3 months and 6 months after transplantation and then at 6-month intervals thereafter. The International Neuroblastoma Re-
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sponse Criteria were used to assess response. 31 Variations in the intensity of MIBG concentration within any single target lesion were not used for determination of response to therapy.
Toxicities were graded according to the National Cancer Institute common toxicity criteria. Endocrine function was assessed by thyroidstimulating hormone, thyroxine, adrenocorticotropic hormone, and cortisol measurements obtained before and after therapy. Cardiac function (echocardiogram, ECG) and pulmonary assessment (chest x-ray, pulmonary function testing in patients older than 6 years of age) were made before therapy, at day 100, and then yearly after transplantation.
Neutrophil recovery was defined as the first of 3 consecutive days of an ANC Ն 0.5 ϫ 10 3 /L. Platelet recovery was defined as the first of 3 consecutive days with a platelet count Ն 20 ϫ 10 3 /L without platelet transfusion support.
RESULTS
Patient Characteristics
Twelve patients were treated on study between May 1998 and September 2000 (Table 1) . 32 All patients had received extensive prior therapy, including eight patients who had received more than one chemotherapy regimen before study entry. Three patients (patients no. 10, 11, and 12) had undergone a previous autologous stem-cell transplantation 6 months to 3 years before enrollment on study. Four patients (patients no. 8, 9, 11, and 12) had MYCN-amplified tumors.
At the time of study entry, eight patients had metastatic and four had localized disease. Bone metastases were present in eight patients, including two patients who exhibited more than 10 sites of abnormal MIBG uptake and two patients with pathologic fractures at the time of 131 I-MIBG therapy. Bone marrow disease was present in six patients. In five of the six, the marrow had isolated tumor rosettes, occupying less than 5% of the marrow biopsy. In one case, the marrow involvement was greater than 50% of the biopsy specimen at the time of 131 I-MIBG therapy. Five patients had pulmonary or mediastinal involvement, and two patients had intra-abdominal lesions, the largest lesion measuring 10 ϫ 8 ϫ 6 cm at the time of MIBG therapy. Ten of 11 patients had a creatinine clearance greater than 100 mL/min/1.73 m 2 at study entry.
Treatment Course
Actual 131 I-MIBG doses ranged from 132 to 484 mCi (median dose, 212 mCi). The 131 I-MIBG infusion was tolerated well in all patients. Patients receiving 132 to 300 mCi 131 I-MIBG required isolation for 48 to 96 hours (median, 72 hours), whereas patients receiving over 300 mCi required 96 to 120 hours after the 131 I-MIBG infusion. The mean whole-body irradiation dose was 2.7 Gy (range, 1.74 to 4.07 Gy). Eight patients received unpurged peripheral stem cells, two received purged peripheral stem cells (patients no. 5 and 2), and two received purged marrow 
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(patients no. 8 and 9) on day 0 of therapy. 26 The median cell dose infused was 3.5 ϫ 10 6 CD34 ϩ cells/kg.
Nonhematologic Toxicity
Regimen-related toxicities are listed in Table 2 . Three patients developed mild nausea/vomiting within 24 hours of the 131 I-MIBG infusion. All 12 patients experienced grade 2 to 3 mucositis, beginning day Ϫ1 to day 2 after transplantation. Fevers developed in all patients, with the onset of fever on day Ϫ1 to day 7 after transplantation. Although no episodes of sepsis were noted, two patients developed alpha-hemolytic streptococcal bacteremia while neutropenic. One episode of P carinii pneumonitis occurred 150 days after transplantation. Dermatologic complications occurred in one patient, with an erythematous skin rash developing in the right axillary region 4 days after MIBG infusion. A skin biopsy specimen of the affected region revealed mild vacuolar interface dermatitis, and no cutaneous neuroblastoma. Two patients developed hematuria, with hemorrhagic cystitis documented by cystoscopy in one of the two cases. The hematuria developed 30 to 40 days after transplantation in both cases, subsequently resolving with intravenous fluids and platelet support. Urinary cultures for bacterial, fungal, and viral organisms were negative. Asymptomatic hypothyroidism, diagnosed by an elevated thyroid-stimulating hormone level at 3 months after transplantation, occurred in two patients. No cases of adrenal insufficiency (on the basis of serum adrenocorticotropic hormone and cortisol levels) have been noted. There were no toxicity-related deaths.
Hematologic Toxicity
Hematologic features are listed in Table 3 . In all 12 patients, neutrophil counts remained stable (Ͼ 1.5 ϫ 10 3 / L) for 2 weeks after the 131 I-MIBG administration. The median time to count nadir (ANC Ͻ 0.5 ϫ 10 3 /L) was day 0 of therapy (range, day Ϫ2 to day 1). The median time to neutrophil recovery was day 10 (range, day 6 to day 31). Eleven of 12 patients achieved an ANC Ն 0.5 ϫ 10 3 by day 15 after transplantation.
The median time to platelet nadir (Ͻ 20 ϫ 10 3 /L) was day 1, with a median time to platelet recovery on day 28 (range, day 7 to day 99). Two patients required platelet transfusions after day 50 because of hematuria.
Response Rates
For the eight patients treated with metastatic disease, three achieved CR and two achieved a partial remission after transplantation. Three of four patients treated for persistent localized disease achieved CR. Responses were seen in bone (Fig 1) , soft tissue (Fig 2) , and marrow. Five of six patients with marrow involvement before therapy had no evidence of disease by biopsy and immunocytology at day 100. Five of eight patients with bone involvement on pretherapy MIBG scans had resolution of MIBG activity in these sites by day 100. All three patients who previously undergone transplantation did not achieve a response by day 100 (two with no response, and one with progressive disease). Patient no. 8, who exhibited more than 10 sites of bony disease and more than 50% marrow involvement at the time of 131 I-MIBG therapy, achieved a complete response by day 100, including normal marrow morphology and immunocytology (per 10 6 cells). Relapse or disease progression has occurred in eight patients, 2 to 13 months (median, 8.5 months) after transplantation. Relapses have occurred in previously unin- volved bony sites (patients no. 1, 2, and 12), in previously involved bony sites (patients no. 8 and 11), in marrow (patients no. 4, 9, and 10), and in a primary abdominal mass (patient no. 11).
DISCUSSION
The feasibility of combining 131 I-MIBG with myeloablative chemotherapy and hematopoietic stem-cell rescue for patients with neuroblastoma was examined in this pilot trial. The median age at the time of initial diagnosis (3.3 years), the percentage of patients with MYCN amplification (33%), and the median time from diagnosis to transplantation (12 months) were similar to that reported in other neuroblastoma trials. 3, 5, 33 Despite extensive prior therapy, toxicity was acceptable and objective responses were observed in this group of patients.
The nonhematologic toxicity of the regimen was limited, with fever/neutropenia and oral mucositis predominantly seen in all patients. Both toxicities occurred during the period of count nadir (after myeloablative chemotherapy), and presumably may have been related more to the intensive chemotherapy than to the 131 I-MIBG. When given as single-agent therapy, 131 I-MIBG has not been previously associated with the development of mucositis. Historically, the incidence of mucositis has been high in patients receiving myeloablative chemotherapy for the treatment of neurboblastoma. 3, 34, 35 The potential for bladder injury was of concern in this trial. Urinary excretion of 131 I-MIBG has been previously well described, with visualization of the bladder readily seen on routine 123 I-and 131 I-MIBG diagnostic scans. The majority of 131 I-MIBG is excreted unchanged in the urine, with 40% to 55% of an administered dose excreted in the first day, and 70% to 90% by the fifth day after administration. 36, 37 In order to minimize 131 I-MIBG contact with bladder epithelium, all patients in this trial had indwelling urinary catheters placed and intravenous hydration administered during the 131 I-MIBG administration. Despite this precaution, hematuria developed after transplantation in two patients, with hemorrhagic cystitis documented by cystos- 
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copy in one of the cases. The potential for bladder epithelial injury will need to be monitored in future 131 I-MIBG trials. The cause of the skin rash that developed 4 days after 131 I-MIBG infusion in one patient remains unclear, as no evidence for cutaneous neuroblastoma was noted on biopsy specimens. No other dermatologic toxicities were observed in this study or in previously reported 131 I-MIBG trials. 19, [21] [22] [23] [24] [25] [26] [27] Although the follow-up has been short (median, 12 months), few late complications have been observed. The use of SSKI administration for 28 days after 131 I-MIBG administration appears to have inhibited thyroid uptake of radiolabeled iodine in the majority of treated patients. The use of more vigorous measures to block thyroid uptake, such as the addition of perchlorate anion, or a greater duration of SSKI therapy may lower the incidence of hypothyroidism even further. Likewise, although 131 I-MIBG will normally concentrate within the adrenal medulla, adrenal insufficiency has not been noted to date. Secondary leukemia was previously reported in a patient who received two courses of single-agent 131 I-MIBG therapy. 23 No cases of secondary leukemia have been noted in our study population to date. Because 131 I-MIBG readily concentrates within the marrow, and as the majority of treated patients will have previously received high-dose alkylator and etoposide therapy, the potential for development of secondary leukemia is present in our study population.
The hematopoietic toxicity of the therapy was acceptable, with 11 of 12 patients engrafting (ANC Ͼ 0.5 ϫ 10 3 /L) within 15 days after transplantation. The dosage of 131 I-MIBG used in this trial (12 mCi/kg) has previously been shown to be myelosuppressive, but not myeloablative, if given as single-agent therapy. 23 Delayed neutrophil recovery was only observed in one case (patient no. 8), who also had the greatest degree of marrow involvement at the time of treatment (Ͼ 50% neuroblasts). I-MIBG concentration within the marrow, particularly within megakaryocytes, has already been well described. 22 Whether marrow precursor cells or stromal cells selectively bind 131 I-MIBG at levels that may lead to prolonged cellular injury is still under investigation.
An important finding in our study was the time to onset of neutropenia (median onset, day 0). Given that marrow suppression will typically occur 21 to 40 days after infusions of 131 I-MIBG, 23 Previous single-agent 131 I-MIBG trials have found a threshold for tumor response, with dosages more than 9 mCi/kg achieving the greatest tumor response. Matthay et al 23 noted responses in 37% of patients treated with single-agent therapy, with 131 I-MIBG dosages ranging from 9 to 18 mCi/kg. Ten (48%) of 21 patients treated with dosages Ն 12 mCi/kg had a response, with no apparent difference in response rates between patients treated with 12 mCi/kg versus those treated with 18 mCi/kg. 23 Our toxicity and response rates were similar to those reported in other trials. [24] [25] [26] [27] However, direct comparisons are difficult to 
2147
make because of the heterogeneous approaches taken in these trials. Klingebiel et al 27 noted responses in eight of 11 patients treated for stage IV disease with a common induction regimen (German Neuroblastoma Trial NB90), followed by consolidation with 131 I-MIBG (15.6 mCi/kg), carboplatin, etoposide, and melphalan chemotherapy, hematopoietic stem-cell rescue, and subsequent anti-GD2 murine or chimeric antibody (ch14.18). With a median observation time of 19 months, nine of 11 children were alive, eight without progression or relapse.
Whether patients in our trial relapsed because of failure of control of in situ disease, or because of reinfusion of undetected tumor cells within the stem-cell or marrow product, is difficult to determine in a trial of this size. Three of the relapses occurred in sites of new disease in patients who had received unpurged stem-cell products. It is likewise difficult to determine whether the responses seen in this trial were principally secondary to the MIBG therapy, to the high-dose chemotherapy, or to the combination of the two. No diagnostic studies were routinely performed on day Ϫ7, immediately before the chemotherapy. Prior singleagent studies have found that MIBG does not usually achieve its maximal effect for at least 4 to 6 weeks after infusion. 18, 20, 22 The determination of optimal candidates for MIBG therapy is still under investigation. Historically, patients with relapsed neuroblastoma have an extremely poor rate of survival, especially if nonlocalized disease is present at the time of relapse. [1] [2] [3] [4] [5] [6] The presence of a chemoresistant relapse or relapse after transplantation are two adverse factors previously reported by Ladenstein et al 4 in a large European trial. In agreement with the report by Ladenstein et al, we noted that patients who had received a prior transplant appeared less responsive to our study therapy. Patients who have a persistent MIBG-avid tumor at the completion of induction therapy, 5 or the presence of more than 100 tumor cells per 100,000 by marrow immunocytology on completion of induction therapy, 39 are known to be at high risk for treatment failure. The addition of 131 I-MIBG to consolidation therapy in these high-risk groups may be considered in the future.
As the patient population is small, larger studies will be required to more adequately assess efficacy and impact on overall survival. This pilot study examined the role of 131 I-MIBG with myeloablative chemotherapy at only one dose level. A multicenter trial is currently in progress, in which dose escalation of both the 131 I-MIBG and the chemotherapy regimen are being examined. In conclusion, the combination of 131 I-MIBG with a fixed dose of myeloablative chemotherapy and autologous stem-cell rescue appears feasible for patients with relapsed or persistent MIBGavid disease. Overall, therapy was well tolerated in this small group of patients, with limited nonhematopoietic toxicity, and responses were seen even in patients with progressive disease. Future trials combining 131 I-MIBG with high-dose chemotherapy are warranted.
